Meeting
2015 ASCO Annual Meeting
Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study.
Authors
Eric Jeffrey Sherman
Memorial Sloan Kettering Cancer Center, New York, NY
Eric Jeffrey Sherman , Alan Loh Ho , Matthew G. Fury , Shrujal S. Baxi , Lara Dunn , Jennifer S Lee , Brynna Lane Lipson , David G. Pfister
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01141309
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6069)
DOI
10.1200/jco.2015.33.15_suppl.6069
Abstract #
6069
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer.
First Author: Eric Jeffrey Sherman
Poster
2014 ASCO Annual Meeting
Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.
First Author: Ignace Vergote
Poster
2013 ASCO Annual Meeting
A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).
First Author: Jochen H. Lorch
Poster
2021 ASCO Annual Meeting
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).
First Author: Eric Jeffrey Sherman